Maria Lucia Katayama

Dr. Maria Lucia Katayama


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2010 in Respiratory Research
Verified
Journal Article
Open access
PDF file
AVAna Paula P Velosa
Ana Paula P Velosa
WTWalcy Rosolia Teodoro
Walcy Rosolia Teodoro
DADaniel M dos Anjos
Daniel M dos Anjos
RKRenata Konno
Renata Konno
COCristiane C Oliveira
Cristiane C Oliveira
NYNatalino H Yoshinari
Natalino H Yoshinari
The purpose of this study was to evaluate collagen deposition, mRNA collagen synthesis and TGF-beta expression in the lung tissue in an experimental model of scleroderma after collagen V-induced nasal tolerance.

3 December 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SMSimone Maistro
Simone Maistro
NTNatalia Teixeira
Natalia Teixeira
GEGiselly Encinas
Giselly Encinas
MKMaria Lucia Katayama
Maria Lucia Katayama
VNVivian Dionisio Tavares Niewiadonski
Vivian Dionisio Tavares Niewiadonski
MFMaria Aparecida Folgueira
Maria Aparecida Folgueira
Approximately 8–15% epithelial ovarian cancer patients are BRCA1 or BRCA2 germline mutation carriers. Brazilian inhabitants may have peculiar genetic characteristics associated with ethnic diversity, and studies focusing on the entire BRCA1/BRCA2 gene sequencing in Brazilian ovarian cancer patients are still lacking. The aim of this study was to evaluate BRCA1/2 mutations, through entire gene sequencing, in a Brazilian population of women with epithelial ovarian cancer. In a cross sectional study performed in one reference centre for cancer treatment in São Paulo, Brazil, 100 patients diagnosed with epithelial ovarian cancer unselected for family history of breast and/or ovarian cancer were included. The complete coding sequence of BRCA1/2 genes was evaluated through Next-Generation or capillary sequencing. Large deletions were investigated through Multiplex Ligation-dependent Probe Amplification (MLPA). Nineteen pathogenic mutations (BRCA1: n = 17 and BRCA2: n = 2) featuring 14 different mutations, including two large deletions in BRCA1 (exon 1–2 deleted and exon 5–7 deleted) were identified. Three mutations were detected more than once (c.3331_3334delCAAG, c.5266dupC and c.4484G > T). Two novel frameshift mutations were identified, one in BRCA1 (c.961_962delTG) and one in BRCA2 (c.1963_1963delC). BRCA1/2 mutations were seen in 35.5% of the patients with first and/or second-degree relatives with breast and/or ovarian cancer. Nineteen variants of uncertain significance (VUS) were detected (BRCA1: n = 2 and BRCA2: n = 17), including five distinct missense variants (BRCA1: c.5348 T > C; BRCA2: c.2350A > G, c.3515C > T, c.7534C > T, and c.8351G > A). Among epithelial ovarian cancer patients unselected for family history of cancer, 19% were BRCA1/2 germline mutation carriers. Almost ¾ of the BRCA mutations, including two large deletions, were detected only once. Our work emphasizes the need of entire gene sequencing and MLPA screening in Brazil.

15 March 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CMCintia Milani
Cintia Milani
MKMaria Lucia Katayama
Maria Lucia Katayama
ELEduardo Carneiro de Lyra
Eduardo Carneiro de Lyra
JWJoEllen Welsh
JoEllen Welsh
LCLaura Tojeiro Campos
Laura Tojeiro Campos
MFMaria Aparecida Folgueira
Maria Aparecida Folgueira
Background: Vitamin D transcriptional effects were linked to tumor growth control, however, the hormone targets were determined in cell cultures exposed to supra physiological concentrations of 1,25(OH)2D3 (50-100nM). Our aim was to evaluate the transcriptional effects of 1,25(OH)2D3 in a more physiological model of breast cancer, consisting of fresh tumor slices exposed to 1,25(OH)2D3 at concentrations that can be attained in vivo. Methods: Tumor samples from post-menopausal breast cancer patients were sliced and cultured for 24 hours with or without 1,25(OH)2D3 0.5nM or 100nM. Gene expression was analyzed by microarray (SAM paired analysis, FDR≤0.1) or RT-qPCR (p≤0.05, Friedman/Wilcoxon test). Expression of candidate genes was then evaluated in mammary epithelial/breast cancer lineages and cancer associated fibroblasts (CAFs), exposed or not to 1,25(OH)2D3 0.5nM, using RT-qPCR, western blot or immunocytochemistry. Results: 1,25(OH)2D3 0.5nM or 100nM effects were evaluated in five tumor samples by microarray and seven and 136 genes, respectively, were up-regulated. There was an enrichment of genes containing transcription factor binding sites for the vitamin D receptor (VDR) in samples exposed to 1,25(OH)2D3 near physiological concentration. Genes up-modulated by both 1,25(OH)2D3 concentrations were CYP24A1, DPP4, CA2, EFTUD1, TKTL1, KCNK3. Expression of candidate genes was subsequently evaluated in another 16 samples by RT-qPCR and up-regulation of CYP24A1, DPP4 and CA2 by 1,25(OH)2D3 was confirmed. To evaluate whether the transcripitonal targets of 1,25(OH)2D3 0.5nM were restricted to the epithelial or stromal compartments, gene expression was examined in HB4A, C5.4, SKBR3, MDA-MB231, MCF-7 lineages and CAFs, using RT-qPCR. In epithelial cells, there was a clear induction of CYP24A1, CA2, CD14 and IL1RL1. In fibroblasts, in addition to CYP24A1 induction, there was a trend towards up-regulation of CA2, IL1RL1, and DPP4. A higher protein expression of CD14 in epithelial cells and CA2 and DPP4 in CAFs exposed to 1,25(OH)2D3 0.5nM was detected. Conclusions: In breast cancer specimens a short period of 1,25(OH)2D3 exposure at near physiological concentration modestly activates the hormone transcriptional pathway. Induction of CYP24A1, CA2, DPP4, IL1RL1 expression appears to reflect 1,25(OH)2D3 effects in epithelial as well as stromal cells, however, induction of CD14 expression is likely restricted to the epithelial compartment.

27 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
GEGiselly Encinas
Giselly Encinas
VSVeronica Y. Sabelnykova
Veronica Y. Sabelnykova
ELEduardo Carneiro de Lyra
Eduardo Carneiro de Lyra
MKMaria Lucia Katayama
Maria Lucia Katayama
SMSimone Maistro
Simone Maistro
MFMaria Aparecida Folgueira
Maria Aparecida Folgueira
Oncotarget | https://doi.org/10.18632/oncotarget.25123 Giselly Encinas, Veronica Y. Sabelnykova, Eduardo Carneiro de Lyra, Maria Lucia Hirata Katayama, Simone Maistro, Pedro Wilson Mompean de Vasconcellos Valle,... Somatic mutations in early onset luminal breast cancer

4 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
MKMaria Lucia Katayama
Maria Lucia Katayama
RVRené Aloísio da Costa Vieira
René Aloísio da Costa Vieira
VAVictor Piana Andrade
Victor Piana Andrade
RRRosimeire Aparecida Roela
Rosimeire Aparecida Roela
LLLuiz Guilherme Cernaglia Aureliano Lima
Luiz Guilherme Cernaglia Aureliano Lima
MFMaria Aparecida Folgueira
Maria Aparecida Folgueira
Breast cancer stromal compartment, may influence responsiveness to chemotherapy. Our aim was to detect a stromal cell signature (using a direct approach of microdissected stromal cells) associated with response to neoadjuvant chemotherapy (neoCT) in locally advanced breast cancer (LABC). The tumor samples were collected from 44 patients with LABC (29 estrogen receptor (ER) positive and 15 ER negative) before the start of any treatment. Neoadjuvant chemotherapy consisted of doxorubicin and cyclophosphamide, followed by paclitaxel. Response was defined as downstaging to maximum ypT1a-b/ypN0. The stromal cells, mainly composed of fibroblast and immune cells, were microdissected from fresh frozen tumor samples and gene expression profile was determined using Agilent SurePrint G3 Human Gene Expression microarrays. Expression levels were compared using MeV (MultiExperiment Viewer) software, applying SAM (significance analysis of microarrays). To classify samples according to tumor response, the order of median based on confidence statements (MedOr) was used, and to identify gene sets correlated with the phenotype downstaging, gene set enrichment analysis (GSEA). Nine patients presented disease downstaging. Eleven sequences (FDR 17) were differentially expressed, all of which (except H2AFJ) more expressed in responsive tumors, including PTCHD1 and genes involved in abnormal cytotoxic T cell physiology, TOX, LY75, and SH2D1A. The following four pairs of markers could correctly classify all tumor samples according to response: PTCHD1/PDXDC2P, LOC100506731/NEURL4, SH2D1A/ENST00000478672, and TOX/H2AFJ. Gene sets correlated with tumor downstaging (FDR < 0.01) were mainly involved in immune response or lymphocyte activation, including CD47, LCK, NCK1, CD24, CD3E, ZAP70, FOXP3, and CD74, among others. In locally advanced breast cancer, stromal cells may present specific features of immune response that may be associated with chemotherapy response.

1 January 2018 in Clinics
Verified
Journal Article
Open access
MCMarina Candido Visontai Cormedi
Marina Candido Visontai Cormedi
MKMaria Lucia Katayama
Maria Lucia Katayama
RGRodrigo Santa Cruz Guindalini
Rodrigo Santa Cruz Guindalini
SFSheila Friedrich Faraj
Sheila Friedrich Faraj
MFMaria Aparecida Folgueira
Maria Aparecida Folgueira
Survival data for young adults (YA) with gastric cancer is conflicting and scarce in Brazil. The aim of this study was to compare the clinicopathological factors and survival rates of younger and older patients with gastric cancer.Hospital registries ...